Financial Performance - The group's revenue for the year ended December 31, 2025, was RMB 4,008.8 million, a decrease of 9.8% compared to RMB 4,446.1 million for the year ended December 31, 2024[2]. - Net profit for the year ended December 31, 2025, was RMB 161.5 million, down 73.0% from RMB 598.3 million in the previous year, primarily due to an impairment of goodwill related to Etern Group Ltd. amounting to RMB 283.3 million[2][7]. - Adjusted net profit under non-IFRS was RMB 455.5 million, a decrease of 24.4% from RMB 602.3 million for the year ended December 31, 2024[2][7]. - Gross profit for the fiscal year was RMB 1,023.5 million, with a gross margin of 25.5%[42]. - Operating profit decreased significantly to RMB 393,425, a decline of 52.0% from RMB 821,144 in the previous year[109]. - Basic and diluted earnings per share for 2025 were RMB 0.27, down from RMB 0.95 in 2024[109]. Cash Flow and Debt Management - The group's operating cash flow for the year ended December 31, 2025, was RMB 950.0 million, an increase of 34.4% compared to the previous year[2]. - Free cash flow for the year ended December 31, 2025, was RMB 466.4 million, a significant increase of 407.0% from the previous year[3]. - The group's interest-bearing debt as of December 31, 2025, was RMB 2,436.2 million, a decrease of RMB 343.0 million or 12.3% from the previous year[3]. - Interest-bearing debt decreased by RMB 343 million year-on-year, down 12.3%, with a debt-to-asset ratio of 28.9%, a decline of 7.4 percentage points compared to the previous year[11]. - Cash and cash equivalents as of December 31, 2025, amount to RMB 429.2 million, with total financial assets at fair value through profit or loss at RMB 259.0 million, resulting in a total cash and cash equivalents increase of 13.4% from RMB 652.9 million in 2024[57]. - Total liabilities as of December 31, 2025, are RMB 3,880.4 million, a decrease of 8.8% from RMB 4,254.9 million in 2024[64]. Operational Highlights - Patient satisfaction increased to 98.54%, up 1.51 percentage points from the previous year, with a goal of achieving 100% satisfaction[8]. - The number of key specialties increased from 8 to 38 over the past three years, enhancing the group's competitive edge in critical care services[9]. - The group operates 17 hospitals focused on oncology and has one under construction, with a total of approximately 1,200 acres of medical land and about 940,000 square meters of medical facilities[9]. - The proportion of revenue from oncology-related services was 44.3% in 2025, showing a stable increase compared to the previous year, with over 102,000 surgeries performed, including a 6.4 percentage point increase in the proportion of high-level surgeries[16]. - The company has established partnerships with over 70 insurance companies to enhance the efficiency and convenience of medical services for commercial insurance patients[18]. Strategic Initiatives - The company is focusing on expanding non-medical insurance services and health management offerings to meet diverse patient needs, driven by increasing disposable income and aging population[18]. - The company has initiated a share repurchase plan of RMB 200 million, having repurchased 13.0252 million shares, which is 2.06% of the total shares before cancellation[13]. - The company plans to enhance its comprehensive medical capabilities focusing on oncology and critical care, and to develop international medical projects to meet diverse patient needs[37]. - The company is actively exploring mergers and acquisitions to capitalize on industry consolidation opportunities[38]. Innovation and Technology - The company has implemented AI applications to enhance operational efficiency and service experience, focusing on AI-assisted personalized precision radiotherapy and imaging diagnosis in oncology[19]. - The company has developed an AI customer service system to improve patient satisfaction through virtual guidance, consultation, health education, and brand promotion[19]. - The company has actively pursued innovative applications of AI in medical scenarios, including the integration of brain-machine interfaces in neurosurgery and rehabilitation[19]. Corporate Governance and ESG - The company is committed to maintaining high corporate governance standards to protect shareholder interests and enhance corporate value[99]. - The audit committee, consisting of three independent non-executive directors, oversees compliance, accounting policies, and financial reporting procedures[102]. - The group has received multiple honors for its ESG efforts, including recognition from the Central Committee of the Communist Party of China and various local governments[31]. - The group’s ESG performance has been rated "A" by Wind, placing it in a leading position among Hong Kong-listed healthcare service companies[34]. Employee and Shareholder Information - The total number of employees as of December 31, 2025, was 7,906, a decrease from 8,169 employees as of December 31, 2024[87]. - Total employee compensation, including directors' remuneration, amounted to RMB 1,331.1 million for the year ending December 31, 2025, down from RMB 1,456.1 million for the year ending December 31, 2024[89]. - The group did not declare any final dividend for the year ended December 31, 2025[83]. - The company has not exercised any stock options during the reporting period[90].
海吉亚医疗(06078) - 2025 - 年度业绩